Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention

摘要: ABSTRACT Background In the treatment of advanced breast cancer, third-generation aromatase inhibitors (AIs) have shown superior efficacy and tolerability compared with tamoxifen megestrol acetate, previous standard endocrine therapies in first- second-line settings, respectively. AIs are now being assessed adjuvant prevention settings. Design Literature review (PubMed search). Results Tamoxifen is currently only option available for therapy chemoprevention postmenopausal women. However, results from ATAC (‘Arimidex’, Tamoxifen, Alone or Combination) trial anastrozole to be more effective than as women hormone-responsive early cancer. Other AIs, including letrozole exemestane, also investigated therapies. setting, at high risk cancer but, given that these healthy subjects, associated an unacceptable rate adverse events. Raloxifene further STAR (Study Raloxifene) trial, while evaluated second IBIS-II (International Breast Intervention Study II). Conclusions particular anastrozole, set change way treated. Effective better-tolerated alternatives may become future.